| APELLIS PHARMACEUTICALS |
| USA |
| Gesundheit |
| US03753U1060 / A2JAAW |
| 1JK (Frankfurt) / APLS (NASDAQ) |
| FRA:1JK, ETR:1JK, 1JK:GR, NASDAQ:APLS |
| - |
| https://www.apellis.com/ |
|
Apellis Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds that inhibit the complement system to treat autoimmune and inflammatory diseases. Its k..
>Volltext.. |
| 1885.1 Mio. EUR |
| 1890.73 Mio. EUR |
| 872.29 Mio. EUR |
| 49.52 Mio. EUR |
| 19.46 Mio. EUR |
| 0.15 EUR |
| 412.22 Mio. EUR |
| 406.48 Mio. EUR |
| 39.39 Mio. EUR |
| 1.45 |
| 13.23% |
| - |
| - |
| - |
| - |
| - |
| APELLIS |
| 31.03.26 |